<DOC>
	<DOC>NCT00535470</DOC>
	<brief_summary>To evaluate the efficacy and safety of topical application of MCH 0.04% in a propylene glycol ointment (PG)in patients with stage I or IIA MF previously treated with MCH 0.02% in a PG or AP ointment who did not achieve a complete response.</brief_summary>
	<brief_title>An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides</brief_title>
	<detailed_description>This is a multi-center, open-label study of patients with previously treated stage I (IA and IB) or IIA MF who have not received a complete response after completing 12 months of treatment in clinical trial (2005NMMF-201-US)to either 0.02% MCH PG or 0.02% MCH in Aquaphor (AP) ointment formulations.</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<criteria>Patients must have completed the treatment phase of the Yaupon Therapeuticssponsored Phase II Pivotal study of MCH 0.02% in either the PG or AP formulation and have not achieved a complete response. Pregnant or nursing females, or males and females of childbearing potential, not using an effective means of contraception</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>